Business
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum
VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research ForumAccepted Abstracts Highlight Advances in AI-Driven Oncology Pipeline\nVANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that two research abstracts have been accepted for presentation at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22 in San Diego, California. The AACR Annual Meeting is a global forum for cancer research, where the world’s leading scientists, clinicians, and biotech innovators gather to unveil next-generation oncology breakthroughs. Rakovina’s acceptance to present highlights growing recognition for its work at the intersection of AI technology and precision cancer therapy. From AI Design to Delivery: Advancing Novel DDR Therapies for Hard-to-Treat Cancers Rakovina will present two abstracts at the meeting. The first abstract: A Novel Brain-Penetrant Dual ATR-mTOR Inhibitor for PTEN-Deficient Cancers, presents the use of the Enki™ generative AI platform to design first-in-class CNS-penetrating molecules that simultaneously inhibit ATR and mTOR, two key drivers of survival in PTEN-deficient cancer cells. PTEN deficiency is found in up to 40% of gliomas and up to 63% of breast cancers, which frequently metastasize to the brain, yet no approved therapy directly addresses this dual vulnerability. Using the Enki™ latent diffusion model to simultaneously optimize potency, selectivity, CNS penetrance, and ADMET properties in collaboration with Variational AI (Vancouver, BC), the team identified and synthesized promising dual inhibitor candidates, with data on efficacy and pharmacokinetics to be presented at the meeting. Title: A novel brain-penetrant dual ATR-mTOR inhibitor for PTEN-deficient cancersDate/Time: April 20, 2026 / 9:00 AM – 12:00 PMSession Category: Experimental and Molecular TherapeuticsSession: DNA Damage and Repair 2Abstract Number: 5034 The second abstract: Development of a Lipid Nanoparticle Formulation of the Bifunctional PARP and HDAC Inhibitor Kt-3283, present...